101 related articles for article (PubMed ID: 10772444)
1. Recurrent NNRTI-induced hepatotoxicity in an HIV-HCV-coinfected patient.
Piroth L; Grappin M; Sgro C; Buisson M; Duong M; Chavanet P
Ann Pharmacother; 2000 Apr; 34(4):534-5. PubMed ID: 10772444
[No Abstract] [Full Text] [Related]
2. NNRTI hepatotoxicity: efavirenz versus nevirapine.
Pulido F; Torralba M
J HIV Ther; 2002 Nov; 7 Suppl 2():S3-16. PubMed ID: 12735215
[No Abstract] [Full Text] [Related]
3. Antiretroviral medication considerations for individuals coinfected with HIV and hepatitis C virus.
Lai AR; Tashima KT; Taylor LE
AIDS Patient Care STDS; 2006 Oct; 20(10):678-92. PubMed ID: 17052138
[TBL] [Abstract][Full Text] [Related]
4. Mitigation of hepato-cellular injury caused by HAART with glycyrrhizin compound in patients co-infected with HIV and HCV.
Yamamoto Y; Yasuoka A; Tachikawa N; Teruya K; Genka I; Yamaguchi M; Yasuoka C; Kikuchi Y; Aoki M; Oka S
Jpn J Infect Dis; 1999 Dec; 52(6):248-9. PubMed ID: 10738365
[No Abstract] [Full Text] [Related]
5. No increased risk of hepatotoxicity in long-term use of nonnucleoside reverse transcriptase inhibitors in HIV-infected patients.
Van Welzen B; Mudrikova T; Arends J; Hoepelman A
HIV Med; 2012 Aug; 13(7):448-52. PubMed ID: 22413955
[TBL] [Abstract][Full Text] [Related]
6. Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors.
Palmon R; Koo BC; Shoultz DA; Dieterich DT
J Acquir Immune Defic Syndr; 2002 Apr; 29(4):340-5. PubMed ID: 11917237
[TBL] [Abstract][Full Text] [Related]
7. Hcv coinfection, an important risk factor for hepatotoxicity in pregnant women starting antiretroviral therapy.
Snijdewind IJ; Smit C; Godfried MH; Nellen JF; de Wolf F; Boer K; van der Ende ME
J Infect; 2012 Apr; 64(4):409-16. PubMed ID: 22227465
[TBL] [Abstract][Full Text] [Related]
8. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.
Sulkowski MS; Thomas DL; Mehta SH; Chaisson RE; Moore RD
Hepatology; 2002 Jan; 35(1):182-9. PubMed ID: 11786975
[TBL] [Abstract][Full Text] [Related]
9. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.
Aranzabal L; Casado JL; Moya J; Quereda C; Diz S; Moreno A; Moreno L; Antela A; Perez-Elias MJ; Dronda F; Marín A; Hernandez-Ranz F; Moreno A; Moreno S
Clin Infect Dis; 2005 Feb; 40(4):588-93. PubMed ID: 15712082
[TBL] [Abstract][Full Text] [Related]
10. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients.
Pineda JA; Mira JA; Gil Ide L; Valera-Bestard B; Rivero A; Merino D; Girón-González JA; Ríos-Villegas MJ; González-Serrano M; Collado A; García-García JA; Carrillo-Gómez R; López-Cortés LF; Gómez-Mateos J
J Antimicrob Chemother; 2007 Dec; 60(6):1347-54. PubMed ID: 17938129
[TBL] [Abstract][Full Text] [Related]
11. [Etravirine in special populations].
Santos Gil Ide L
Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():40-5. PubMed ID: 20116627
[TBL] [Abstract][Full Text] [Related]
12. Upper gastrointestinal bleeding may unmask didanosine-associated portal hepatopathy in HIV/HCV co-infected patients.
Vispo E; Maida I; Barreiro P; Moreno V; Soriano V
HIV Clin Trials; 2008; 9(6):440-4. PubMed ID: 19203910
[TBL] [Abstract][Full Text] [Related]
13. No hepatotoxicity found for etravirine.
AIDS Patient Care STDS; 2008 Dec; 22(12):1022. PubMed ID: 19097262
[No Abstract] [Full Text] [Related]
14. ART and liver-related mortality in HIV/HCV.
Carter M
IAPAC Mon; 2003 Dec; 9(12):315. PubMed ID: 15055165
[No Abstract] [Full Text] [Related]
15. Nucleoside analogues and mitochondrial toxicity.
Fleischer R; Boxwell D; Sherman KE
Clin Infect Dis; 2004 Apr; 38(8):e79-80. PubMed ID: 15095236
[TBL] [Abstract][Full Text] [Related]
16. HIV/HCV co-infection: clinical and therapeutic challenges.
Ensoli F; Sirianni MC
AIDS; 2002 Jul; 16(10):1419-20. PubMed ID: 12131219
[No Abstract] [Full Text] [Related]
17. HIV and hepatitis C coinfection.
Matthews GV; Dore GJ
J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 1):1000-8. PubMed ID: 18707597
[TBL] [Abstract][Full Text] [Related]
18. Managing symptomatic drug-induced liver injury in HIV-hepatitis C virus-coinfected patients: a role for interferon.
McGovern BH; Birch C; Zaman MT; Bica I; Stone D; Quirk JR; Davis B; Zachary K; Basgoz N; Graeme-Cook F; Gandhi RT
Clin Infect Dis; 2007 Nov; 45(10):1386-92. PubMed ID: 17968840
[TBL] [Abstract][Full Text] [Related]
19. Optimal treatment of nevirapine-associated hepatotoxicity remains uncertain.
Bundow D; Rosoff L; Aboulafia DM
AIDS Read; 2001 Nov; 11(11):577-80. PubMed ID: 11789021
[TBL] [Abstract][Full Text] [Related]
20. Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100 mg once daily in HIV/hepatitis C virus-coinfected patients.
Merchante N; López-Cortés LF; Delgado-Fernández M; Ríos-Villegas MJ; Márquez-Solero M; Merino D; Pasquau J; García-Figueras C; Martínez-Pérez MA; Omar M; Rivero A; Macías J; Mata R; Pineda JA;
AIDS Patient Care STDS; 2011 Jul; 25(7):395-402. PubMed ID: 21688986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
